Abstract 323P
Background
The new pandemic SARS-CoV-19 requires a new strategy in the oncology care in all over the world. Kazakhstan, with a population of 18.2 million, is a first country that re-introduced restrictions due to an increased level of the infected population. According to new rules, all admissions to the oncology hospitals and special care are based on negative RT-PCR tests and with no radiological evidence of pneumonia.
Methods
Patients with confirmed COVID-19 infection with clinical symptoms are treated in accordance with the National Guidelines of the COVID-19 management by Joint Commission on Quality of Health Services, Ministry of Health of the Republic of Kazakhstan. For these patients, special oncology treatment should be postponed. Special care of the SARS-CoV-2 symptoms is provided in infectious hospitals. As for July 21, there are 71,838 of the COVID-19 cases registered in Kazakhstan, put of which 3,585 are mortal ones. According to the National Cancer Register, there are 187,856 cancer patients in Kazakhstan. In order to evaluate the number of the oncological patients with COVID-19, we received data from the National Electronic Database in the period from March 2020 to July 2020.
Results
The total number of the infected cancer patients is 178 and it varies in different regions. The majority of the cases are registered in the Karaganda region with 43 cancer patients (24%), Nur-Sultan city - 19 cases (10.6%), and the Kostanay region -16 cases (9%) with the total numbers of the COVID-19 infected population in these regions of 7,401; 8,832 and 2,071 cases respectively. Overall in Kazakhstan, the total number of the deceased from COVID-19 patients with cancer registered is 14. In the Karaganda region there are 6 deceased patients, 2 - in Kostanay, 2 - in Kyzyl-Orda, and 2 – in the North-Kazakhstan regions.
Conclusions
We consider all the cancer patients as a risk group, due to the COVID-19 infection, however, we stratified patients with cancer into three following categories: patients who require immediate special treatment; patients, to whom special treatment can be postponed; and those who can be supervised distantly and for who special treatment is not required for up to 3 month.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kaidarova Dilyara.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
77P - Dual targeting oxidative phosphorylation and glycolysis in triple-negative breast cancers: En route to effective inhibition of tumour metabolism
Presenter: Alexander Scherbakov
Session: e-Poster Display Session
78P - Novel allogeneic cell immunotherapy for advanced cancers
Presenter: Ratnavelu Kananathan
Session: e-Poster Display Session
86P - The impact of sarcopenia on chemotherapy toxicity and survival rate among colorectal cancer patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Timotius Hariyanto
Session: e-Poster Display Session
87P - Predictive risk factors and online nomograms for colon cancer with synchronous liver metastasis
Presenter: Yajuan Zhu
Session: e-Poster Display Session
88P - Research of radiomics based on indeterminate lung nodules predicting prognosis of LARC patients
Presenter: Zhang Zhiyuan
Session: e-Poster Display Session
89P - Biomarker analysis of regorafenib dose escalation study (RECC study): A phase II multicenter clinical trial in Japan
Presenter: Masanobu Enomoto
Session: e-Poster Display Session
90P - The role of miR-133a-3p/SP1/IGF1R axis in the progression of colorectal cancer
Presenter: Hui Li
Session: e-Poster Display Session
91P - Prognostic biomarker of clinical outcome in locally advanced rectal cancer in Chinese patients
Presenter: Sandy Ho
Session: e-Poster Display Session
92P - Development and validation of risk and prognostic nomograms for bone metastases in advanced colorectal cancer patients
Presenter: Nan Wang
Session: e-Poster Display Session
93P - Assessment of nutritional status of colorectal cancer patients in a tertiary government hospital
Presenter: Rogelio Velasco
Session: e-Poster Display Session